Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 10 shares of common stock through a deferral plan.

Summary

• Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 10 shares of common stock on July 15, 2024.
• The shares were acquired at a price of $950.46 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Ms. Johnson's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows director confidence, but it is not a major event.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this transaction is consistent with those requirements.
• Many directors and officers of public companies use deferral plans as part of their compensation, and this transaction is similar to those seen at other large pharmaceutical companies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates director confidence in the company.

Key Dates

Keywords

insider trading, Form 4, director, stock acquisition, share deferral, Eli Lilly, LLY